한빛사논문
- 조회126
연세대학교
Hyeong Yun Kim 1,8, Seongmin Cho 1,8, Sang Bum Kim 6, Ee Chan Song 1, Wonchul Jung 1, Yun Gyeong Shin 1, Ji Hun Suh 1, Jihye Choi 1, Ina Yoon 2, Uijoo Kim 1, Hamin Ban 1, Sungkyo Hwang 1, Jeongwon Mun 1, Joohee Park 1, Nayoung Kim 1, Youngjin Lee 7, Myung Hee Kim 7, Sunghoon Kim 1,3,4,5
1Institute for Artificial Intelligence and Biomedical Research (AIBI), Medicinal Bioconvergence Research Center, College of Pharmacy, Yonsei University, Incheon 21983, Republic of Korea
2College of Pharmacy, Yonsei University, Incheon 21983, Republic of Korea
3College of Medicine, Gangnam Severance Hospital, Yonsei University, Seoul 06273, Republic of Korea
4Institute for Convergence Research and Education in Advanced Technology, Yonsei University, Incheon 21983, Republic of Korea
5Interdisciplinary Graduate Program in Integrative Biotechnology & College of Medicine, Gangnam Severance Hospital, Yonsei University, Incheon 21983, Korea
6College of Pharmacy, Sahmyook University, Seoul 01795, Korea
7Microbiome Convergence Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea
8H.Y. Kim and S. Cho contributed equally to this article.
Corresponding author: Sunghoon Kim, Ph.D.
Abstract
Cancer vaccines have been developed as a promising way to boost cancer immunity. However, their clinical potency is often limited due to the imprecise delivery of tumor antigens. To overcome this problem, we conjugated an endogenous toll like receptor (TLR)2/6 ligand, UNE-C1, to human papilloma virus type 16 (HPV-16)-derived peptide antigen, E7, and found that the UNE-C1-conjugated cancer vaccine (UCV) showed significantly enhanced antitumor activity in vivo compared to the noncovalent combination of UNE-C1 and E7. The combination of UCV with PD-1 blockades further augmented its therapeutic efficacy. Specifically, the conjugation of UNE-C1 to E7 enhanced its retention in inguinal draining lymph nodes, the specific delivery to dendritic cells and E7 antigen-specific T-cell responses, and antitumor efficacy in vivo compared to the noncovalent combination of the two peptides. These findings suggest the potential of UNE-C1 derived from human cysteinyl-tRNA synthetase 1 (CARS1) as a unique vehicle for the specific delivery of cancer antigens to antigen-presenting cells via TLR2/6 for the improvement of cancer vaccines.
논문정보
- Research article
- 2024년 07월 (BRIC 등록일 2024-07-29)
- 국내 연구진
- 의약학 > 약학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
